Navigation Links
AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
Date:11/29/2011

WELLESLEY HILLS, Mass., Nov. 29, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that AMG 277 discriminates against S1P3 receptor by 50-fold and that the S1P1 lead compounds will be offered December 8, 2011 in a sealed bid sale.  These assets were generated by Epix Pharmaceuticals, Inc. and Amgen.

AMG 277 has 57-nM functional EC50 for hS1P1 receptor and discriminates against S1P3 receptor by 50-fold.  It displayed efficacy in a DTH model with ED70 of 1.0 mpk.  AMG 277 was tested in FIH-enabling toxicology studies.    

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – jffinnjr@finnwarnkegayton.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, LLP Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
(Date:12/5/2016)... Ill. , Dec. 5, 2016 For ... score on the 2017 Human Rights Campaign Foundation,s ... The CEI is a national benchmarking tool used to ... bisexual, and transgender (LGBT) employee equality. For ... Survey to help companies gauge their equality efforts, culture ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... on perampanel presented at the 2016 Annual Meeting of ... marketed as FYCOMPA® CIII, is indicated as an adjunctive ... with or without secondarily generalized seizures and primary generalized ... 12 years of age and older. Please see Important ...
Breaking Medicine Technology:
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... Missouri (PRWEB) , ... December 05, 2016 , ... ... ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has always ... treatment accessible to as many people as possible. In that spirit, Castlewood ...
(Date:12/5/2016)... ... ... U.S. Apple Association (USApple) begins the holiday giving season by donating $17,800 to ... Buy an Apple, Help a Student fundraising campaign. , Winning ideas ... their families; solar technology to efficiently process compost; and iPads to enhance student learning. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... portfolio company, today announced it has acquired the assets of Frankfurt, Germany ... a subsidiary of Chiltern International and focuses on clinical trial drug packaging, ...
Breaking Medicine News(10 mins):